NOVEL, SUSTAINED-RELEASE, DRY-POWDER INHALABLE FORMULATION FOR MONTELUKAST SODIUM

Abstract

The objective of this research is to improve therapy for asthma patients by developing a drug delivery platform for inhalation of a sustained-release, dry-powder formulation for Montelukast Sodium (MS). Montelukast Sodium microparticles were prepared with solvent evaporation process. The microspheres were then blended with an inhalable lactose additive (Lactohale), which acts as a carrier molecule in the formulation. Total four formulations A, B, C and D were prepared with 1:1, 1:2, 1:3, 1:4 ratio of MS:Eudragit RS100. The developed formulations were studied for physicochemical properties, in vitro drug relase and Anderson cascade impaction studies. Based on dissolution presentation, the 1:1 ratio of MS:Eudragit RS100 produces in vitro release 93.71% at 12 h and having particle size of microparticles (D0.5 mum) 4.92+/-0.7 and the pulmonary deposition of dry powder 38.4 +/- 3.53 (respiratory fraction in percentage).